Department of Ophthalmology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea.
J Glaucoma. 2014 Sep;23(7):446-8. doi: 10.1097/IJG.0b013e3182946505.
To evaluate the long-term intraocular pressure (IOP) changes after intravitreal injection of bevacizumab for age-related macular degeneration.
A total of 83 eyes that received intravitreal injections of bevacizumab for age-related macular degeneration were enrolled. IOP measurements at baseline, 6, 12, 18, and 24 months, and at the last follow-up after injection were analyzed. On the basis of the median number of injections, the changes in IOP were compared.
The mean number of injections was 3.71±1.62. There was no significantly higher elevation than baseline IOP (14.11±2.76 mm Hg) after multiple intravitreal injections of bevacizumab (P>0.05). In the group which had ≥4 injections, mean IOP measurements were not higher compared with the group which had <4 injections during the follow-up period (P>0.05). In the patients with preexisting glaucoma (3 eyes), there were no significant increases of IOP during the follow-up period.
IOP elevation was not observed during the long-term follow-up period. In addition, the numbers of injection and preexisting glaucoma did not affect IOP changes.
评估玻璃体内注射贝伐单抗治疗年龄相关性黄斑变性的长期眼压（IOP）变化。
共纳入 83 只接受玻璃体内注射贝伐单抗治疗年龄相关性黄斑变性的眼。分析基线时、注射后 6、12、18 和 24 个月以及最后一次随访时的 IOP 测量值。根据注射中位数，比较 IOP 的变化。
平均注射次数为 3.71±1.62。多次玻璃体内注射贝伐单抗后，IOP 升高无明显高于基线 IOP（14.11±2.76mmHg）（P>0.05）。在接受≥4 次注射的组中，与接受<4 次注射的组相比，在随访期间的平均 IOP 测量值并没有更高（P>0.05）。在 3 只存在青光眼的患者中，在随访期间 IOP 没有显著升高。
在长期随访期间未观察到眼压升高。此外，注射次数和青光眼的存在并不影响 IOP 的变化。
